vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $19.1M, roughly 1.8× Americas Gold & Silver Corp). Americas Gold & Silver Corp runs the higher net margin — -82.3% vs -299.9%, a 217.6% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -28.0%).
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
KPTI vs USAS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $19.1M |
| Net Profit | $-102.2M | $-15.7M |
| Gross Margin | — | 34.2% |
| Operating Margin | -52.4% | — |
| Net Margin | -299.9% | -82.3% |
| Revenue YoY | 11.6% | -28.0% |
| Net Profit YoY | -232.0% | 2.8% |
| EPS (diluted) | $-7.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | — | ||
| Q3 25 | $44.0M | $19.1M | ||
| Q2 25 | $37.9M | — | ||
| Q1 25 | $30.0M | — | ||
| Q4 24 | $30.5M | — | ||
| Q3 24 | $38.8M | $26.5M | ||
| Q2 24 | $42.8M | — | ||
| Q1 24 | $33.1M | — |
| Q4 25 | $-102.2M | — | ||
| Q3 25 | $-33.1M | $-15.7M | ||
| Q2 25 | $-37.3M | — | ||
| Q1 25 | $-23.5M | — | ||
| Q4 24 | $-30.8M | — | ||
| Q3 24 | $-32.1M | $-16.2M | ||
| Q2 24 | $23.8M | — | ||
| Q1 24 | $-37.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 34.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 23.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -52.4% | — | ||
| Q3 25 | -34.6% | — | ||
| Q2 25 | -64.3% | — | ||
| Q1 25 | -110.8% | — | ||
| Q4 24 | -102.4% | — | ||
| Q3 24 | -67.8% | — | ||
| Q2 24 | -65.7% | — | ||
| Q1 24 | -101.9% | — |
| Q4 25 | -299.9% | — | ||
| Q3 25 | -75.2% | -82.3% | ||
| Q2 25 | -98.2% | — | ||
| Q1 25 | -78.2% | — | ||
| Q4 24 | -100.8% | — | ||
| Q3 24 | -82.7% | -60.9% | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | -112.8% | — |
| Q4 25 | $-7.02 | — | ||
| Q3 25 | $-3.82 | — | ||
| Q2 25 | $-4.32 | — | ||
| Q1 25 | $-2.77 | — | ||
| Q4 24 | $-2.33 | — | ||
| Q3 24 | $-3.85 | — | ||
| Q2 24 | $-2.97 | — | ||
| Q1 24 | $-4.85 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $39.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $50.2M |
| Total Assets | $108.4M | $234.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | — | ||
| Q3 25 | $37.7M | $39.1M | ||
| Q2 25 | $38.7M | — | ||
| Q1 25 | $38.8M | — | ||
| Q4 24 | $62.5M | — | ||
| Q3 24 | $72.8M | — | ||
| Q2 24 | $84.8M | — | ||
| Q1 24 | $30.6M | — |
| Q4 25 | $-292.9M | — | ||
| Q3 25 | $-269.3M | $50.2M | ||
| Q2 25 | $-238.9M | — | ||
| Q1 25 | $-205.9M | — | ||
| Q4 24 | $-186.0M | — | ||
| Q3 24 | $-159.6M | $53.1M | ||
| Q2 24 | $-132.1M | — | ||
| Q1 24 | $-169.0M | — |
| Q4 25 | $108.4M | — | ||
| Q3 25 | $96.2M | $234.7M | ||
| Q2 25 | $104.9M | — | ||
| Q1 25 | $127.7M | — | ||
| Q4 24 | $164.4M | — | ||
| Q3 24 | $189.5M | — | ||
| Q2 24 | $214.0M | — | ||
| Q1 24 | $204.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $-12.5M |
| Free Cash FlowOCF − Capex | — | $-41.3M |
| FCF MarginFCF / Revenue | — | -216.5% |
| Capex IntensityCapex / Revenue | 0.0% | 150.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | — | ||
| Q3 25 | $-5.9M | $-12.5M | ||
| Q2 25 | $-18.7M | — | ||
| Q1 25 | $-39.0M | — | ||
| Q4 24 | $-25.8M | — | ||
| Q3 24 | $-19.5M | $2.4M | ||
| Q2 24 | $-38.5M | — | ||
| Q1 24 | $-43.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-41.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-25.9M | — | ||
| Q3 24 | — | $-11.2M | ||
| Q2 24 | — | — | ||
| Q1 24 | $-43.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -216.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -84.7% | — | ||
| Q3 24 | — | -42.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | -132.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 150.8% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.0% | 51.2% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.62× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
USAS
Segment breakdown not available.
